phase 1_completion
saveRevolution Medicines Inc — daraxonrasib (Phase I Trial Completion)
community read0 votes
Therapy area: Oncology. Indication: Colorectal Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Solid Tumor
Data sources
globaldata
Found something off?
same company · ±60 days · 1
related news · 8
- oncliveASCO 2026: All Eyes Are on Daraxonrasib and a Wave of Novel Targeted Therapies in GI Malignancies
- oncliveFive Under 5: Top Oncology Videos for the Week of 5/3
- oncliveThe OncFive: Top Oncology Articles for the Week of 5/3
- oncliveBiomarker-Directed Therapies Move the GI Oncology Paradigm Beyond a One-Size-Fits-All Approach: With Michael J. Pishvaian, MD, PhD
- oncliveDaraxonrasib Monotherapy Elicits Meaningful Responses in Previously Treated, RAS-Mutated Pancreatic Cancer
- statSTAT+: Pharmalittle: We’re reading about Sanofi and an FDA voucher, FDA rethinking a rejection, and more
- oncliveDr McGregor on the DAD-IO Trial of Sacituzumab Govitecan and EV in Metastatic Urothelial Carcinoma
- oncliveCases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Cancer
comments(0)
5-min edit window · permanent after that